Integer Holdings (ITGR) Stock Forecast & Price Target

Integer Holdings is a compelling long-term medical device manufacturing platform because it sits in structurally attractive end markets, has deep customer integration as a CDMO, and derives the majority of its business from Cardio & Vascular (60% of 2025 revenues) and Cardiac Rhythm Management & Neuromodulation (36%), where design, quality, and reliability create meaningful switching costs. Despite the reduction in 2026 guidance, the company’s fundamentals still appear resilient given its scale, its streamlined portfolio after the October 2024 divestiture of Electrochem, and management’s confidence that it should return to 200 bps above market organic sales growth in 2027, which suggests the current softness is more cyclical than structural. The announcement in August 2026 of an agreement to sell the company to KKR for $127 per share in cash further underscores the value of Integer’s asset base and customer relationships, while its broad geographic footprint across the United States, Ireland, Puerto Rico, Costa Rica, and the Rest of the World supports diversification and operational reach.

Integer Holdings is facing a fundamentally mixed setup: while 2Q26 revenue of $464.1 million declined 2.6% year-over-year and adjusted EPS slipped to $1.60 from $1.65, the company also lost revenue from Other Markets due to a divestiture and saw Cardio & Vascular sales fall 2%, indicating that core growth remains uneven. Although Q1 sales of $440 million beat expectations and adjusted EPS of $1.20 exceeded estimates, the company’s gross margin of 24.9% and adjusted operating margin of 7.2% both missed targets, suggesting that profitability remains under pressure even when top-line execution improves. The negative outlook is further reinforced by the pending KKR acquisition, which has led Integer to stop providing forward guidance or holding a Q2 earnings call, limiting visibility into future fundamentals and making the shares less compelling despite the company’s durable franchise and the core EP market still being intact.